Journal News

JLR: A close-up of nascent HDL formation

Laurel Oldach
January 01, 2019

Oil and water don’t mix. But our aqueous blood is full of hydrophobic lipids — including cholesterol. To travel via the bloodstream, those lipids must hitch a ride on an amphipathic carrier. In a paper in the Journal of Lipid Research, scientists at Boston University report an advance in our mechanistic understanding of how one such carrier forms.

“Lipoproteins are like boats that deliver and remove cargoes of fatty substances to and from our cells,” said David Atkinson, chair of the physiology and biophysics department at Boston University School of Medicine and senior author on the JLR paper.

The subset of those “boats” that carry cholesterol and other lipids to the liver from other parts of the body are called high-density lipoproteins, or HDL, aka “good cholesterol.” HDL can remove cholesterol from distal cells — such as macrophages in the walls of arteries, where cholesterol accumulation can lead to heart attacks — and deliver it to liver cells, a process known as reverse cholesterol transport. The liver disposes of excess cholesterol by converting it into bile acids secreted into the small intestine.

According to Atkinson, a biophysicist, most of what is known about HDL formation comes from experiments that take a cell biological tack. In such studies, he said, “You can see (HDL formation) happening, and you can quantitate what happens, but you don’t understand the driving interactions that cause it to happen.”

HDL is built on a scaffold protein, apolipoprotein A-I. This apoA-I is thought to collect cholesterol and phospholipids from the cell membrane. Atkinson’s team wanted to better understand that process.

Lipoprotein particleA model of a high-density lipoprotein particle shows apolipoprotein A-I in pink, phospholipids in gray and cholesterol in yellow.Wu et al/JBC 2009ApoA-I depends on a lipid transporter protein, ABCA1, that pumps cholesterol from the inner to the outer leaflet of the cell membrane. Because the cholesterol that ABCA1 transfers usually ends up bound to apoA-I, some researchers suspected a physical interaction between apoA-I and ABCA1. Others argued that cholesterol and phospholipids could diffuse passively and bind to apoA-I.

“Even if you demonstrate that apoA-I binds to the cell surface, you don’t actually know that it’s bound to ABCA1. It’s just bound to the cell surface,” Atkinson said. So he asked his team to see if they could “demonstrate that interaction actually happening in the isolated components.”

The team, led by graduate student Minjing Liu and supported by Xiaohu Mei and Haya Herscovitz, used isolated apoA-I and ABCA1 to test for a physical interaction. They were able to show immunoprecipitation of apoA-I with purified ABCA1.

The lab earlier had designed a mutant apoA-I with a little extra wiggle in an already flexible hinge region. For this study, they used the mutant to show that higher flexibility increased apoA-I lipidation, or the formation of nascent HDL. The team has not yet tested whether the extra-flexible mutant binds to ABCA1 better or whether binding of either form of apoA-I activates ABCA1.

But about one thing Atkinson is certain: “It’s the apoA-I/ABCA1 interaction which then enables the nascent HDL particle formation to happen as the membrane components are being transported out by ABCA1.”

Increasing reverse cholesterol transport may be a way to reduce atherosclerosis and heart disease. Atkinson is optimistic about the promise of understanding the physiological processes better.

“Translational research might be in vogue,” he said, “but remember that if you don’t do foundational basic discovery research, you will not have anything to translate.”

Laurel Oldach

Laurel Oldach is a science writer for the ASBMB.

Join the ASBMB Today mailing list

Sign up to get updates on articles, interviews and events.

Latest in Science

Science highlights or most popular articles

Stopping the devil in the dust
Feature

Stopping the devil in the dust

April 07, 2020

As clinicians, veterinarians and research scientists close in on potential vaccines for the devastating fungal illness Valley fever, the largest barrier likely remains outside the lab.

Life's little oscillations
News

Life's little oscillations

April 05, 2020

Concentrations of molecules rise and fall, genes switch on and off, and circadian clocks keep time. These biochemical fluctuations are crucial for myriad biological needs, and cells couldn't function without them.

A small trial finds that hydroxychloroquine is not effective for treating coronavirus
News

A small trial finds that hydroxychloroquine is not effective for treating coronavirus

April 05, 2020

Despite the recent approval of this drug for use against COVID-19, questions remain as to the efficacy of this treatment.

Team Cryo ices Mass Spec’s hopes in JBC Methods Madness tourney
Journal News

Team Cryo ices Mass Spec’s hopes in JBC Methods Madness tourney

April 03, 2020

In the inaugural JBC Methods Madness Tournament, cryo­–EM/ET gave structural biologists around the world something to cheer about, beating mass spectrometry 51% to 49% —​ a margin thinner than shaved ice. 

A small army of researchers races to build a coronavirus interactome
News

A small army of researchers races to build a coronavirus interactome

April 01, 2020

Scientists at eight institutions in the U.S. and Europe have used a protein interaction map to identify 69 drugs that might work against SARS-CoV-2, the virus that causes COVID-19.

Parkinson's  Awareness Month
Health Observance

Parkinson's Awareness Month

April 01, 2020

It is the second-most common progressive neurodegenerative disease, occurring in 1% of people over the age of 60 and in 5% of people over 85.